Mdma: Research Areas Needing More Emphasis

The summary for the Mdma: Research Areas Needing More Emphasis grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Mdma: Research Areas Needing More Emphasis: The purpose of this PA is to provide an optimally comprehensive, strategic, and balanced MDMA (3,4-methylenedioxymethamphetamine) research program, given the upsurge in MDMA abuse worldwide, including its abuse outside the rave scene. Although researchers have made great strides in characterizing MDMAs neural mechanisms and neurotoxicity, it is necessary now to focus on specific areas of MDMA research, across all research disciplines, urgently needing our attention. For the purpose of this PA, the term MDMA is defined as 3,4-methylenedioxymethamphetamine and its very close structural analogues, such as p-methoxyamphetamine (PMA), p-methoxymethamphetamine (PMMA), and 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA), insofar as they share specific subjective, discriminative stimulus, or toxicological properties with 3,4-methylenedioxymethamphetamine; however, methamphetamine and other amphetamines that are characterized by neurotoxic effects on central dopaminergic systems in experimental animals are not included in this definition. Ecstasy is defined as a preparation (usually a tablet) supposed by its users to contain MDMA.
Federal Grant Title: Mdma: Research Areas Needing More Emphasis
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-04-152
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse Research Programs
Current Application Deadline: No deadline provided
Original Application Deadline: Multiple Receipt Dates - See Link to Full Announce
Posted Date: Sep 08, 2004
Creation Date: Dec 07, 2006
Archive Date: Feb 03, 2007
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Small businesses Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education City or township governments For profit organizations other than small businesses Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Others (see text field entitled "Additional Information on Eligibility" for clarification) County governments Native American tribal organizations (other than Federally recognized tribal governments) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Independent school districts
Additional Information on Eligibility
Eligible agencies of the Federal Government are eligible to apply. Foreign institutions are eligible to apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
Similar Government Grants
Opioid Use Disorder in Pregnancy (R01)
Exploiting HIV and/or Host Genomic Information to Understand HIV Compartments or Reactivat...
Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01)
HIV-associated neuropathic pain and opioid interaction (R01)
Pharmacogenomics of Anti-retroviral Therapy in People Who Inject Drugs (R01)
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Simulation Modeling and Systems Science to Address Health Disparities (R01-Clinical Trial ...
Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of NIDDK (R01...
NCI National Clinical Trials Network (NCTN)--Network Lead Academic Participating Sites (UG...
Maintaining Immunity After Immunization (U01 - Clinical Trial Optional)
Human Tumor Atlases (HTA) Research Centers (U2C) is not endorsed by, or affiliated with, any government agency. Copyright ©2017